283 related articles for article (PubMed ID: 35767258)
61. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy.
Shen J; Qi W; Dai J; Leng S; Jiang K; Zhang Y; Ran S; Li C; Wen T
Chin Med J (Engl); 2021 Dec; 135(3):301-308. PubMed ID: 34958539
[TBL] [Abstract][Full Text] [Related]
62. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
Papatheodoridis G; Dalekos G; Sypsa V; Yurdaydin C; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Mangia G; Gatselis N; Keskin O; Savvidou S; de la Revilla J; Hansen BE; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
J Hepatol; 2016 Apr; 64(4):800-6. PubMed ID: 26678008
[TBL] [Abstract][Full Text] [Related]
63. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
64. Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate.
Ha Y; Chon YE; Kim MN; Lee JH; Hwang SG
Sci Rep; 2020 Aug; 10(1):13537. PubMed ID: 32782369
[TBL] [Abstract][Full Text] [Related]
65. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
Trinh S; Le AK; Chang ET; Hoang J; Jeong D; Chung M; Lee MH; Wang U; Henry L; Cheung R; Nguyen MH
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):948-956.e1. PubMed ID: 30130625
[TBL] [Abstract][Full Text] [Related]
66. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis.
Liu H; Han CL; Tian BW; Ding ZN; Yang YF; Ma YL; Yang CC; Meng GX; Xue JS; Wang DX; Dong ZR; Chen ZQ; Hong JG; Li T
Expert Rev Gastroenterol Hepatol; 2023; 17(6):623-633. PubMed ID: 37148261
[TBL] [Abstract][Full Text] [Related]
67. Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma.
Kim JH; Sinn DH; Kim K; Kim H; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Gut Liver; 2016 Nov; 10(6):939-947. PubMed ID: 27282264
[TBL] [Abstract][Full Text] [Related]
68. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L
J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952
[TBL] [Abstract][Full Text] [Related]
69. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study.
Qi W; Shen J; Dai J; Wu Y; Zhang Y; Leng S; Gao F; Ran S; Peng W; Zhang X; Wen T; Li C
Cancer Med; 2021 Dec; 10(23):8421-8431. PubMed ID: 34643050
[TBL] [Abstract][Full Text] [Related]
70. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
Kim JH; Kim YD; Lee M; Jun BG; Kim TS; Suk KT; Kang SH; Kim MY; Cheon GJ; Kim DJ; Baik SK; Choi DH
J Hepatol; 2018 Nov; 69(5):1066-1073. PubMed ID: 30075230
[TBL] [Abstract][Full Text] [Related]
71. Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir.
Lim TS; Lee HW; Lee JI; Kim IH; Lee CH; Jang BK; Chung WJ; Yim HJ; Suh SJ; Seo YS; Lee HA; Yu JH; Lee JW; Kim SG; Kim YS; Park SY; Tak WY; Kim SS; Cheong JY; Jeong SW; Jang JY; Rou WS; Lee BS; Kim SU;
J Viral Hepat; 2020 Oct; 27(10):1052-1060. PubMed ID: 32383246
[TBL] [Abstract][Full Text] [Related]
72. A multi-centre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy.
Kim SU; Chon YE; Seo YS; Lee HW; Lee HA; Kim MN; Min IK; Park JY; Kim DY; Ahn SH; Tak WY; Kim BK; Park SY
J Viral Hepat; 2020 Dec; 27(12):1352-1358. PubMed ID: 32852880
[TBL] [Abstract][Full Text] [Related]
73. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy.
Kao WY; Tan EC; Lee HL; Huang YH; Huo TI; Chang CC; Chiou JF; Hou MC; Wu JC; Su CW
Aliment Pharmacol Ther; 2023 Jun; 57(11):1299-1312. PubMed ID: 36914943
[TBL] [Abstract][Full Text] [Related]
74. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
[TBL] [Abstract][Full Text] [Related]
75. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs.
Tsai MC; Chen CH; Hu TH; Lu SN; Lee CM; Wang JH; Hung CH
J Formos Med Assoc; 2017 Jul; 116(7):512-521. PubMed ID: 27720344
[TBL] [Abstract][Full Text] [Related]
76. Tenofovir disoproxil fumarate on the risk of hepatocellular carcinoma in chronic hepatitis B patients with failure to preceding treatments: A nationwide cohort study.
Lee J; Kim GA; Kim HJ; Cho S; Ko MJ; Lim YS
J Viral Hepat; 2021 Aug; 28(8):1150-1159. PubMed ID: 33934466
[TBL] [Abstract][Full Text] [Related]
77. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
78. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
79. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
[TBL] [Abstract][Full Text] [Related]
80. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.
Sohn W; Cho JY; Kim JH; Lee JI; Kim HJ; Woo MA; Jung SH; Paik YH
Clin Mol Hepatol; 2017 Jun; 23(2):170-178. PubMed ID: 28506056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
